Valuation: PAVmed Inc.

Market Cap 37.23M 32.15M 30.21M 27.48M 51.66M 3.56B 52.51M 354M 138M 1.78B 140M 137M 5.92B P/E 2026 *
-1.44x
P/E 2027 * -2.63x
Enterprise Value 37.23M 32.15M 30.21M 27.48M 51.66M 3.56B 52.51M 354M 138M 1.78B 140M 137M 5.92B EV / Sales 2026 *
226x
EV / Sales 2027 * 62x
Free-Float
50.01%
Yield 2026 *
-
Yield 2027 * -
1 day+9.70%
1 week+9.70%
Current month+5.05%
1 month-13.62%
3 months-20.37%
6 months-50.24%
Current year-21.50%
1 week 4.19
Extreme 4.19
5.27
1 month 4.19
Extreme 4.19
5.85
Current year 3.85
Extreme 3.85
28.44
1 year 3.85
Extreme 3.85
28.44
3 years 3.85
Extreme 3.85
270
5 years 3.85
Extreme 3.85
4,365
10 years 3.85
Extreme 3.85
6,520.5
Manager TitleAgeSince
Compliance Officer 62 2023-03-31
Chief Executive Officer 60 2014-06-25
Director of Finance/CFO 69 2017-03-20
Director TitleAgeSince
Director/Board Member 60 2014-09-30
Chairman 60 2014-06-25
Director/Board Member 71 2014-12-31
Date Insider Type Main position Quantity % Market Cap.
9/30/25 Free

Director

150,000 0.6839%
9/30/25 Free

Chief Executive Officer

150,000 0.6839%
9/30/25 Free

Director

150,000 0.6839%
Change 5-day change 1-year change 3-year change Capi.($)
+9.70%+9.70%-61.46%-95.43% 37.23M
-1.28%-0.96%+20.30%+11.24% 218B
-0.71%-1.13%-4.02%-19.91% 142B
-1.68%+4.14%-17.85%+31.80% 139B
+0.27%+5.11%-49.76%+0.72% 75.11B
-1.04%+2.10%+17.05%+16.26% 52.8B
+0.69%-0.51%-16.49%-15.46% 50.66B
-0.51%+1.75%+24.61%+22.39% 41.95B
-0.32%+1.31%+41.37%+49.96% 40.49B
-0.14%+2.68%+0.40%+4.27% 33.28B
Average +0.50%+2.42%-4.59%+0.58% 79.35B
Weighted average by Cap. -0.82%+1.12%+0.51%+9.16%

Financials

2026 *2027 *
Net sales 165K 143K 134K 122K 229K 15.78M 233K 1.57M 614K 7.9M 619K 606K 26.26M 600K 518K 487K 443K 833K 57.37M 846K 5.71M 2.23M 28.73M 2.25M 2.2M 95.48M
Net income -22.05M -19.04M -17.89M -16.27M -30.59M -2.11B -31.1M -210M -81.97M -1.06B -82.77M -80.97M -3.51B -19.5M -16.84M -15.83M -14.39M -27.06M -1.86B -27.5M -185M -72.5M -934M -73.21M -71.62M -3.1B
Net Debt - -
Logo PAVmed Inc.
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
Employees
41
Date Price Change Volume
26-08-14 US$5.200 +9.70% 27,056
26-08-13 US$4.740 +12.59% 125,736
26-08-12 US$4.210 -10.62% 279,067
26-08-11 US$4.710 -0.84% 348,224
26-08-10 US$4.750 +0.21% 13,665
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.200USD
Average target price
36.00USD
Spread / Average Target
+592.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PAVM Stock